Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Free Cash Flow: 2009-2024

Historic Free Cash Flow for Iovance Biotherapeutics (IOVA) over the last 15 years, with Dec 2024 value amounting to -$364.1 million.

  • Iovance Biotherapeutics' Free Cash Flow fell 46.17% to -$89.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$351.8 million, marking a year-over-year increase of 5.94%. This contributed to the annual value of -$364.1 million for FY2024, which is 5.22% up from last year.
  • Latest data reveals that Iovance Biotherapeutics reported Free Cash Flow of -$364.1 million as of FY2024, which was up 5.22% from -$384.1 million recorded in FY2023.
  • Over the past 5 years, Iovance Biotherapeutics' Free Cash Flow peaked at -$251.9 million during FY2020, and registered a low of -$384.1 million during FY2023.
  • Moreover, its 3-year median value for Free Cash Flow was -$364.1 million (2024), whereas its average is -$353.8 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first crashed by 51.94% in 2020, then increased by 5.22% in 2024.
  • Over the past 5 years, Iovance Biotherapeutics' Free Cash Flow (Yearly) stood at -$251.9 million in 2020, then decreased by 5.39% to -$265.5 million in 2021, then dropped by 17.95% to -$313.2 million in 2022, then fell by 22.65% to -$384.1 million in 2023, then grew by 5.22% to -$364.1 million in 2024.